Molecular pathology of lung cancer: Current status and future directions

Tuberculosis and Respiratory Diseases

Volumn 77, Issue 2, 2014, Pages 49-54

  Roh, Mee Sook ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Biological markers; Lung neoplasms; Molecular diagnostic techniques

Indexed keywords

AFATINIB; AZD 4547; BRIVANIB; BUPARLISIB; CABOZANTINIB; CRIZOTINIB; DABRAFENIB; DACOMITINIB; DASATINIB; ERLOTINIB; GEFITINIB; NERATINIB; PICTILISIB; PILARALISIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; S 49076; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB;

CANCER PATIENT; GENE MUTATION; GENOME; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR PATHOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE; TUMOR GENE;

EID: 84907938125     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2014.77.2.49     Document Type: Review

References (37)

1. Lindeinan NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase in hibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8: 823-59.
2. Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014:464:347-58.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epider mal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med 2004:350: 2129-39.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocar cinoma. N Engl J Med 2009:361:947-57.
5. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishi- kawa S, et al. Identification of the transforming EML4-ALK fu sion gene in non-small-cell lung cancer. Nature 2007:448:561- 6.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
8. Dacic S, Nikiforova MN. Present and future molecular testing of lung carcinoma. Adv Anat Pathol 2014;21:94-9.
9. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014;232:121-33.
10. Caglc PT, Allen TC, Olsen RJ. Lung cancer biomarkers: pres ent status and future developments. Arch Pathol Lab Med 2013;137:1191-8.
11. Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biol ogy of lung cancer. J Thorac Dis 2013;5 Suppl 5:S479-90.
12. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome se quencing using reversible terminator chemistry. Nature 2008; 456:53-9.
13. Summerer D. Enabling technologies of genomic-scale se quence enrichment for targeted high-throughput sequencing. Genomics 2009:94:363-8.
14. Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour 2011, 11:759-69.
15. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epider mal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
16. Dearden S, Stevens I, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013:24: 2371-6.
17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to ge fitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
18. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK- positive lung cancer. Clin Cancer Res 2009;15:3143-9.
19. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, Mc Donald NT, et al. ROS1 rearrangements define a unique mo lecular class of lung cancers. J Clin Oncol 2012;30:863-70.
20. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nam-mo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
21. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of pa tients with non-small-cell lung cancer harboring BRAF muta tions. J Clin Oncol 2011:29:3574-9.
22. Sadiq AA, Salgia R. MET as a possible target for non-small- cell lung cancer. J Clin Oncol 2013;31:1089-96.
23. Engelman JA, ZejnuHahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
24. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau- Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003.
25. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharif-nia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351.
26. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al. Phosphoinositide 3-kinase (PI3K) path way alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012; 18:6771-83.
27. Abdulkareem IH, Blair M. Phosphatase and tensin homo- logue deleted on chromosome 10. Niger Med 1 2013:54:79-86.
28. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichi- hara E, et al. Vandetanib is effective in jEGFfl-mutant lung can cer cells with PTEN deficiency. Exp Cell Res 2013:319:417-23.
29. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011:1:78-89.
30. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respira tory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011:6:244-85.
31. Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, et al. Guideline recommendations for EGFR mutation testing in lung cancer: proposal of the Korean Cardiopulmonary Pa thology Study Group. Korean I Pathol 2013:47:100-6.
32. Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, et al. Guideline recommendations for testing of ALK gene rear rangement in lung cancer: A proposal of the Korean Cardio pulmonary Pathology Study Group. Korean J Pathol 2014:48: 1-9.
33. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013:24:577-85.
34. Persson K, Hamby K, Ugozzoli LA. Four-color multiplex re verse transcription polymerase chain reaction-overcoming its limitations. Anal Biochem 2005;344:33-42.
35. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Gen et 2013;45:1113-20.
36. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adeno carcinoma with massively parallel sequencing. Cell 2012:150: 1107-20.
37. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Na ture 2012:489:519-25.